Immunocore Archives | Be Korea-savvy

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untreated metastatic uveal melanoma OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 21 October 2023 (Korea Bizwire) – Immunocore Holdings plc (Nasdaq: IMCR), [...]

Immunocore Presents Phase 3 Data Comparing Tebentafusp with Investigator’s Choice in the Clinical Trial Plenary Session at the American Association for Cancer Research 2021 Annual Meeting

OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, April 12 (Korea Bizwire) – Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial [...]